Drug intelligence / Profile preview

cyclophosphamide + prednisolone

Development stage: Phase 3
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Cyclophosphamide + prednisolone is a combination chemotherapy regimen used in the treatment of various conditions including multiple myeloma, lymphoma, and membranous nephropathy. Cyclophosphamide is an alkylating agent that works by interfering with DNA replication in rapidly dividing cells, while prednisolone is a corticosteroid with anti-inflammatory and immunosuppressive properties. This combination can be administered in different dosing schedules, including continuous low-dose oral administration or intermittent intravenous administration, depending on the condition being treated and patient factors.

Other names: cyclophosphamide and prednisolonecyclophosphamide plus prednisolonecyclophosphamide-prednisolone

Targets

DNAGR (Glucocorticoid receptor)

Beyond the preview

Go deeper on cyclophosphamide + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + prednisolone.